Cargando…

Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses

Rheologically structured vehicle (RSV) gels were developed as delivery systems for vaginal mucosal vaccination with an HIV-1 envelope glycoprotein (CN54gp140). RSVs comprised a mucoadhesive matrix-forming and vaginal fluid absorbing polymer. The mucoadhesive and rheological properties of the RSVs we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Curran, Rhonda M., Donnelly, Louise, Morrow, Ryan J., Fraser, Carol, Andrews, Gavin, Cranage, Martin, Malcolm, R. Karl, Shattock, Robin J., Woolfson, A. David
Formato:	Texto
Lenguaje:	English
Publicado:	Elsevier Science 2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2824087/ https://www.ncbi.nlm.nih.gov/pubmed/19747994 http://dx.doi.org/10.1016/j.vaccine.2009.08.088

Ejemplares similares

P11-11. Stable lyophilised gel vehicles for vaginal administration of recombinant C-clade HIV-1 trimeric CN54gp140
por: Donnelly, L, et al.
Publicado: (2009)

Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms
por: Donnelly, Louise, et al.
Publicado: (2011)

P11-12. A novel vaginal ring device for the sustained delivery of recombinant C-clade HIV-1 CN54gp140
por: Morrow, RJ, et al.
Publicado: (2009)

Antibody responses after intravaginal immunisation with trimeric HIV-1(CN54) clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation
por: Cranage, Martin P., et al.
Publicado: (2011)

Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations
por: Pattani, Aditya, et al.
Publicado: (2012)

Optimising CN54gp140 plasmid delivery by comparing intramuscular and intradermal vaccination combinations with and without electroporation
por: Mann, JF, et al.
Publicado: (2012)

CN54gp140: product characteristics, peclinical and clinical use - recombinant glycoprotein for HIV immunization
por: Katinger, D, et al.
Publicado: (2012)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen()
por: Mann, J.F.S., et al.
Publicado: (2012)

Antigen-specific T lymphocyte responses elicited by a DNA – MVA HIV CN54gp140 immunization regime are significantly altered by the TLR4 adjuvant GLA
por: McKay, PF, et al.
Publicado: (2012)

Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability
por: Kong, Leopold, et al.
Publicado: (2016)

Phase I Randomised Clinical Trial of an HIV-1(CN54), Clade C, Trimeric Envelope Vaccine Candidate Delivered Vaginally
por: Lewis, David J., et al.
Publicado: (2011)

Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate
por: Visciano, Maria Luisa, et al.
Publicado: (2013)

P19-54 LB. Interrogating the membrane-proximal external region (MPER) of HIV-1 gp140
por: Jeffs, S, et al.
Publicado: (2009)

Characterization and Immunogenicity of HIV Envelope gp140 Zera(®) Tagged Antigens
por: Ximba, Phindile, et al.
Publicado: (2020)

Enhanced Immunogenicity of HIV-1 Envelope gp140 Proteins Fused to APRIL
por: Isik, Gözde, et al.
Publicado: (2014)

Optimization and validation of an ELISA assay for the determination of antibody responses to CN54gp140 and AIDSVAX BE for use in the Phase IIb PrEPVacc vaccine trial
por: Gombe, Ben, et al.
Publicado: (2022)

One-step sequence and structure-guided optimization of HIV-1 envelope gp140
por: Malladi, Sameer Kumar, et al.
Publicado: (2020)

P11-09. Mucosal vaccination with a transferrin-gp140 conjugate via the nasal but not vaginal route elicits robust systemic and vaginal IgG and IgA responses
por: Mann, JF, et al.
Publicado: (2009)

Antigenicity of soluble HIV gp140 trimers reveals differences in solution conformation for differing HIV strains
por: Gearhart, TL, et al.
Publicado: (2012)

Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers
por: Koch, Kathrin, et al.
Publicado: (2017)

P14-06. Phase 1 safety and immunogenicity randomised controlled trial of a vaginal gp140 vaccine
por: Lewis, DJ, et al.
Publicado: (2009)

Inverse dose-response to gp140 YU2 foldon trimer formulated with aluminum phosphate and ISCOMATRIX® adjuvants
por: Wilson, A, et al.
Publicado: (2012)

Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice
por: Buffa, Viviana, et al.
Publicado: (2012)

P19-42. Engineering, expression and antigenic and immunogenic characterization of novel soluble clade A/B heterotrimeric gp140-envelope glycoproteins
por: Sellhon, G, et al.
Publicado: (2009)

Stability and neutralization capacity of a novel mosaic HIV-1 gp140 trimer in a guinea pig model
por: Nkolola, JP, et al.
Publicado: (2012)

Production and Immunogenicity of Soluble Plant-Produced HIV-1 Subtype C Envelope gp140 Immunogens
por: Margolin, Emmanuel, et al.
Publicado: (2019)

Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques
por: Zurawski, Gerard, et al.
Publicado: (2016)

A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens
por: Kratochvil, Sven, et al.
Publicado: (2017)

Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers
por: Morris, Charles D., et al.
Publicado: (2017)

Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination
por: Kratochvil, Sven, et al.
Publicado: (2017)

The role of intermolecular disulfide bonding in deposition of GP140 in the extracellular matrix
Publicado: (1984)

Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2013)

Mucosal Application of gp140 Encoding DNA Polyplexes to Different Tissues Results in Altered Immunological Outcomes in Mice
por: Mann, Jamie F. S., et al.
Publicado: (2013)

Corrigendum: Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination
por: Kratochvil, Sven, et al.
Publicado: (2018)

HIV-1 envelope trimer elicits higher neutralizing antibody responses than monomeric gp120
por: Kovacs, JM, et al.
Publicado: (2012)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2014)

Retraction: Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector
Publicado: (2020)

Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals Infected with Clade A and B Viruses
por: Mouquet, Hugo, et al.
Publicado: (2011)

P11-06. Intravaginal administration of HIV-1ZM96 gp140 augments systemic and mucosal antibody responses following systemic priming with adjuvanted protein
por: Cranage, M, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_a905tr25dogqdlfvo7sba1i4r5